Charles Ryan, MD: Bone-Targeted Therapy
Would you consider bone-targeted therapy for this patient, and why?
CASE: Metastatic Prostate Cancer (Part 2)
Mathew J is a 61 year old African American male who presented to his primary care physician with lower urinary tract symptoms, including sporadic hematuria. He complains of abdominal pain and low back pain starting four months ago and increasing in frequency. Prior medical history includes non-insulin dependent diabetes mellitus, well-controlled on metformin since 2006. The patient was referred to urology for further evaluation. ng/ml.
During his most recent follow-up exam, the patient complained of intermittent back pain and increasing fatigue.
- Digital rectum exam revealed nodular prostate /L
- Serum PSA level; 129 ng/ml
- Alkaline phosphatase, 258
- TRUS/prostate biopsy: 53 gram prostate, 12/12 cores (+), Gleason 4 + 5
- CT indicates blastic lesions to lumbar spine and pelvis
- Bone Scan positive for T/L spine, pelvis, right femur, scapula
- ECOG performance status, 1
BXCL701 Gains Fast Track Designation for mCRPC Treatment
February 13th 2024The FDA has granted fast track designation to BXCL701 with an immune checkpoint inhibitor for metastatic small cell neuroendocrine prostate cancer resistant to chemotherapy and showing no evidence of microsatellite instability.
Read More
